Young-Jin Son

Mr. Young-Jin Son


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 December 2021 in Organic & Biomolecular Chemistry
Verified
Journal Article
Closed access
PDF file
HHHee-Jong Hwang
Hee-Jong Hwang
YSYoung-Jin Son
Young-Jin Son
DKDahyun Kim
Dahyun Kim
JLJusuk Lee
Jusuk Lee
YSYun-Jeong Shin
Yun-Jeong Shin
MCMarco A. Ciufolini
Marco A. Ciufolini
We report the first total synthesis of micrococcin P2 (MP2, 1) by a diversity-oriented route that incorporates a number of refinements relative to earlier syntheses. Biological data regarding the activity of 1 against a range of human pathogens are also provided. Furthermore, we disclose a chemical property of MP2 that greatly facilitates medicinal chemistry work in the micrococcin area and describe a method to obtain MP2 by fermentation in B. subtilis.

11 July 2022 in Journal of Natural Products
Verified
Journal Article
Closed access
YSYoung-Jin Son
Young-Jin Son
YKYoung-Rok Kim
Young-Rok Kim
SOSang-Hun Oh
Sang-Hun Oh
SJSungji Jung
Sungji Jung
MCMarco A. Ciufolini
Marco A. Ciufolini
HPHyunjoo Pai
Hyunjoo Pai

5 October 2023 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
DKDahyun Kim
Dahyun Kim
JLJusuk Lee
Jusuk Lee
CSClovis Shyaka
Clovis Shyaka
JKJin-Hwan Kwak
Jin-Hwan Kwak
HPHyunjoo Pai
Hyunjoo Pai
HHHee-Jong Hwang
Hee-Jong Hwang

19 May 2022 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
DKDahyun Kim
Dahyun Kim
YKYoung-Rok Kim
Young-Rok Kim
HHHee-Jong Hwang
Hee-Jong Hwang
MCMarco A. Ciufolini
Marco A. Ciufolini
JLJusuk Lee
Jusuk Lee
JKJin-Hwan Kwak
Jin-Hwan Kwak
The US Centers for Disease Control and Prevention (CDC) lists Clostridioides difficile as an urgent bacterial threat. Yet, only two drugs, vancomycin and fidaxomicin, are approved by the FDA for the treatment of C. difficile infections as of this writing, while the global pipeline of new drugs is sparse at best. Thus, there is a clear and urgent need for new antibiotics against that organism. Herein, we disclose that AJ-024, a nitroimidazole derivative of a 26-membered thiopeptide, is a promising anti-C. difficile lead compound. Despite their unique mode of action, thiopeptides remain largely unexploited as anti-infective agents. AJ-024 combines potent in vitro activity against various strains of C. difficile with a noteworthy safety profile and desirable pharmacokinetic properties. Its time-kill kinetics against a hypervirulent C. difficile ribotype 027 and in vivo (mouse) efficacy compare favorably to vancomycin, and they define AJ-024 as a valuable platform for the development of new anti-C. difficile antibiotics.

24 January 2023 in ACS Chemical Biology
Verified
Journal Article
Closed access
YSYoung-Jin Son
Young-Jin Son
HHHee-Jong Hwang
Hee-Jong Hwang
YKYonghoon Kwon
Yonghoon Kwon

28 September 2018
Verified
Journal Article
Closed access
KKKwang-Jin Kim
Kwang-Jin Kim
SYSung-Hwa You
Sung-Hwa You
YLYongjin Lee
Yongjin Lee
Chanmi ParkChanmi Park
Chanmi Park
GKGeun-Joong Kim
Geun-Joong Kim
YSYoung-Jin Son
Young-Jin Son